Compare KKR & Co Inc (KKR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Eli Lilly And Co — how do they compare? KKR & Co Inc trades at $97.61 (market cap $87.07B), while Eli Lilly And Co trades at $1,161.77 (market cap $1.02T). The key difference: Eli Lilly And Co is far larger — about 11.7× KKR & Co Inc's market cap, and KKR & Co Inc pays the higher dividend (0.77%). Which is the better fit depends on your goals.
| KKR | LLY | |
|---|---|---|
Market Cap | $87.07B | $1.02T |
Sector | Financials | Health |
52-Week High | $152.16 | $1.24K |
52-Week Low | $83.88 | $625.65 |
Enterprise Value | $12.59B | $1.06T |
Dividend Yield | 0.77% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $96.72, down 4.19% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $1.39, beating estimates, and maintains strong analyst support with 24 buy ratings. Recent developments include a $1.3 billion renewable energy joint venture in South Korea and the acquisition of EDF Power Solutions' North American operations for $4.2 billion, highlighting strategic expansion.
The outlook for KKR is positive, supported by robust deal activity and a favorable analyst consensus price target of $124.33. Key risks include execution of large acquisitions and market sensitivity to interest rate changes. Revenue is projected to grow to $20.4 billion in 2026, with net income margin improving to 14.51%, offering potential upside if operational targets are met.
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
